Modulation of adrenal aldosterone release by oxidative modification of low-density lipoprotein

American Journal of Hypertension

Volumn 23, Issue 10, 2010, Pages 1061-1068

  Ansurudeen, Ishrath ^a,c   Pietzsch, Jens ^b   Graessler, Juergen ^a   Ehrhart Bornstein, Monika ^a   Saha, Sarama ^a   Bornstein, Stefan R ^a   Kopprasch, Steffi ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

aldosterone release; aldosterone synthase; blood pressure; ERK; H295R cells; hypertension; LDL; oxidized LDL; sensitivity to angiotensin II

Indexed keywords

ANGIOTENSIN II; HYPOCHLORITE; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NATIVE LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG;

ADRENAL CORTEX CELL; ALDOSTERONE RELEASE; ARTICLE; CHEMICAL ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIPID OXIDATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEROIDOGENESIS; WESTERN BLOTTING;

ADRENAL CORTEX; ADRENAL GLANDS; ALDOSTERONE; ANGIOTENSIN II; BLOTTING, WESTERN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; HYPOCHLOROUS ACID; LIPOPROTEINS, LDL; OXIDANTS; RECEPTORS, LDL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STEROIDS; STIMULATION, CHEMICAL; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 77956877683     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2010.118     Document Type: Article

References (37)

1. Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J 2008; 7:10.
2. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S, Sowers JR. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007; 293: H2009-H2023.
3. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci 2007; 113:267-278.
4. Capponi AM. Regulation of cholesterol supply for mineralocorticoid biosynthesis. Trends Endocrinol Metab 2002; 13:118-121.
5. Graessler J, Pietzsch J, Westendorf T, Julius U, Bornstein SR, Kopprasch S. Glycoxidised LDL isolated from subjects with impaired glucose tolerance increases CD36 and peroxisome proliferator-activator receptor gamma gene expression in macrophages. Diabetologia 2007; 50:1080-1088.
6. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84:1381-1478.
7. Ou HC, Chou FP, Lin TM, Yang CH, Sheu WH. Protective effects of honokiol against oxidized LDL-induced cytotoxicity and adhesion molecule expression in endothelial cells. Chem Biol Interact 2006; 161:113.
8. Kopprasch S, Pietzsch J, Westendorf T, Kruse HJ, Grässler J. The pivotal role of scavenger receptor CD36 and phagocyte-derived oxidants in oxidized low density lipoprotein-induced adhesion to endothelial cells. Int J Biochem Cell Biol 2004; 36:460-471.
9. Tertov VV, Kaplun VV, Orekhov AN. In vivo oxidized low density lipoprotein: degree of lipoprotein oxidation does not correlate with its atherogenic properties. Mol Cell Biochem 1998; 183:141-146.
10. Bachem MG, Wendelin D, Schneiderhan W, Haug C, Zorn U, Gross HJ, SchmidKotsas A, Grünert A. Depending on their concentration oxidized low density lipoproteins stimulate extracellular matrix synthesis or induce apoptosis in human coronary artery smooth muscle cells. Clin Chem Lab Med 1999; 37:319-326.
11. Masella R, Varì R, DArchivio M, Santangelo C, Scazzocchio B, Maggiorella MT, Sernicola L, Titti F, Sanchez M, Di Mario U, Leto G, Giovannini C. Oxidised LDL modulate adipogenesis in 3T3-L1 preadipocytes by affecting the balance between cell proliferation and differentiation. FEBS Lett 2006; 580:2421-2429.
12. Brannian JD. Expression and function of a scavenger lipoprotein pathway in porcine luteal cells. Biol Reprod 1997; 56:221-228.
13. Kajiwara K, Yanagihara N, Ioka T, Tsutsui M, Yashiro A, Toyohira Y, Nakashima Y, Izumi F. Modification of low density lipoprotein potentiates its inhibitory effect on catecholamine secretion in cultured bovine adrenal medullary cells. Naunyn Schmiedebergs Arch Pharmacol 1999; 360:99-102.
14. Higashijima M, Nawata H, Kato K, Ibayashi H. Studies on lipoprotein and adrenal steroidogenesis: I. Roles of low density lipoprotein- and high density lipoproteincholesterol in steroid production in cultured human adrenocortical cells. Endocrinol Jpn 1987; 34:635-645. (Pubitemid 19001416)
15. Kopprasch S, Pietzsch J, Ansurudeen I, Graessler J, Krug AW, Ehrhart-Bornstein M, Bornstein SR. Prediabetic and diabetic in vivo modification of circulating low-density lipoprotein attenuates its stimulatory effect on adrenal aldosterone and cortisol secretion. J Endocrinol 2009; 200:45-52.
16. Pietzsch J, Subat S, Nitzsche S, Leonhardt W, Schentke KU, Hanefeld M. Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim Biophys Acta 1995; 1254:77-88.
17. Kopprasch S, Leonhardt W, Pietzsch J, Kühne H. Hypochlorite-modified lowdensity lipoprotein stimulates human polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites, enzyme secretion, and adhesion to endothelial cells. Atherosclerosis 1998; 136:315-324.
18. Kontush A, Kohlschütter A, Beisiegel U. Physical properties of oxidized lipoproteins. Biochem Mol Biol Int 1995; 37:707-716.
19. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER. Determination of carbonyl content in oxidatively modified proteins. Meth Enzymol 1990; 186:464-478.
20. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976; 15:212-216.
21. Kraemer FB. Adrenal cholesterol utilization. Mol Cell Endocrinol 2007; 265-266: 42-45.
22. Azhar S, Leers-Sucheta S, Reaven E. Cholesterol uptake in adrenal and gonadal tissues: the SR-BI and selective pathway connection. Front Biosci 2003; 8:s998-1029.
23. Fujita T. Aldosterone in salt-sensitive hypertension and metabolic syndrome. J Mol Med 2008; 86:729-734.
24. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150:776-783.
25. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol 2001; 28:783-791.
26. Kavanagh IC, Symes CE, Renaudin P, Nova E, Mesa MD, Boukouvalas G, Leake DS, Yaqoob P. Degree of oxidation of low density lipoprotein affects expression of CD36 and PPARgamma, but not cytokine production, by human monocytemacrophages. Atherosclerosis 2003; 168:271-282.
27. Takei A, Huang Y, Lopes-Virella MF. Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis 2001; 154:79-86.
28. Tanigawa H, Miura S, Zhang B, Uehara Y, Matsuo Y, Fujino M, Sawamura T, Saku K. Low-density lipoprotein oxidized to various degrees activates ERK1/2 through Lox-1. Atherosclerosis 2006; 188:245-250.
29. El-Bassiouni EA, Helmy MH, El-Zoghby SM, El-Nabi Kamel MA, Hosny RM. Relationship between level of circulating modified LDL and the extent of coronary artery disease in type 2 diabetic patients. Br J Biomed Sci 2007; 64:109-116.
30. Kopprasch S, Pietzsch J, Kuhlisch E, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M, Kühne H, Julius U, Graessler J. In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 2002; 51:3102-3106.
31. Uno M, Kitazato KT, Nishi K, Itabe H, Nagahiro S. Raised plasma oxidised LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatr 2003; 74:312-316.
32. Gorog DA, Ahmed N, Davies GJ. Elevated plasma lipid peroxide levels in angina pectoris and myocardial infarction. Cardiovasc Pathol 2002; 11:153-157.
33. Namgaladze D, Kollas A, Brüne B. Oxidized LDL attenuates apoptosis in monocytic cells by activating ERK signaling. J Lipid Res 2008; 49:58-65.
34. Natarajan R, Yang DC, Lanting L, Nadler JL. Key role of P38 mitogen-activated protein kinase and the lipoxygenase pathway in angiotensin II actions in H295R adrenocortical cells. Endocrine 2002; 18:295-301.
35. Otis M, Gallo-Payet N. Role of MAPKs in angiotensin II-induced steroidogenesis in rat glomerulosa cells. Mol Cell Endocrinol 2007; 265-266:126-130.
36. Taketa K, Matsumura T, Yano M, Ishii N, Senokuchi T, Motoshima H, Murata Y, Kim-Mitsuyama S, Kawada T, Itabe H, Takeya M, Nishikawa T, Tsuruzoe K, Araki E. Oxidized low density lipoprotein activates peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARgamma through MAPK-dependent COX-2 expression in macrophages. J Biol Chem 2008; 283: 9852-9862.
37. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev 2005; 10:7-13.